Libtayo (cemiplimab)

pCPA File Number: 21794

Negotiation Status:

Concluded without agreement

Indication(s):

Basal cell carcinoma (BCC), locally advanced or metastatic, previously treated with a hedgehog pathway inhibitor

Sponsor/Manufacturer:

Sanofi-Aventis Canada Inc.

CDA-AMC Project Number:

PC0260-000

pCPA Engagement Letter Issued:

2022-10-03

Negotiation Process Concluded:

2023-07-28